The National Institutes of Health will soon launch a phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
The COVID Research Program is rapidly enrolling patients from New Jersey, which has one of the world’s highest concentrations of COVID-19 patients. Atlantic Health System offers a study sponsored by TScan Therapeutics, Inc., a leading T cell therapeutics company in Waltham, Massachusetts, focused on identifying the precise way the human immune system recognizes and responds to infections like COVID-19 or other diseases, like cancers. TScan has developed a novel technology that enables them to identify the natural targets of T cells.
A Rutgers University expert who is leading a series of Remdesivir trials for people with COVID-19 is available to discuss the drug as a possible treatment as well as preliminary positive results from the trials. “As seen in a news…
A very high level of a protein known as suPAR in the blood of patients with COVID-19 may be a predictor of severe respiratory failure, according to new research published in the Journal of Critical Care on April 30.
More than 800 employees from Rutgers, Robert Wood Johnson University Hospital and University Hospital are participating in a pioneering study
A new study from the Icahn School of Medicine at Mount Sinai suggests that blood clots, especially in the lungs, may play a role in severe cases of COVID-19.
Canada institutions are pooling their scientific expertise to develop an extraordinary immunization program using passive plasma to fight COVID-19.
Rush University Medical Center is participating in a new clinical trial to test the effectiveness of the drug remdesivir in the treatment of coronavirus disease 2019 (COVID-19).